Fox Run Management L.L.C. Has $893,000 Stock Holdings in Pfizer Inc. $PFE

Fox Run Management L.L.C. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 68.9% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 36,851 shares of the biopharmaceutical company’s stock after selling 81,660 shares during the quarter. Fox Run Management L.L.C.’s holdings in Pfizer were worth $893,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter valued at about $27,000. Curio Wealth LLC raised its stake in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares in the last quarter. Bayforest Capital Ltd acquired a new stake in Pfizer in the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. bought a new stake in Pfizer during the second quarter worth approximately $29,000. Finally, WPG Advisers LLC acquired a new position in Pfizer during the first quarter valued at approximately $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.45 on Monday. The firm has a market capitalization of $138.99 billion, a PE ratio of 13.00, a PEG ratio of 0.81 and a beta of 0.54. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The business’s 50 day moving average is $24.74 and its 200-day moving average is $24.38.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 100.00%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research note on Wednesday. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.18.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.